NanoPhoria Bioscience nanophoria.com

Nanophoria is a preclinical biotech company pioneering inhalable cardiovascular therapies via a non-viral, nano-in-micro delivery of biologics. The company is developing a proprietary platform for tissue-directed delivery of therapeutic peptides and RNAs, using biomimetic calcium-phosphate nanoparticles that can be formulated for inhalation or other administration routes. The lead product, NP-MP1, is a three-level inhalable dry powder formulation that carries a proprietary mimetic peptide (MP) into cardiomyocytes via a lung-to-heart route. After inhalation, microparticles reach the deep lung, dissolve to release MP-loaded nanoparticles, which then enter the bloodstream and are taken up by heart muscle cells. Once inside, the peptide modulates L-type calcium channel (LTCC) trafficking, restoring their physiological function and potentially correcting contractile defects in heart failure. The Nanophoria team unites expertise in nanomedicine, RNA/peptide therapeutics, and translational cardiology. Underpinned by strong preclinical proof�-of-concept�including studies in large animal heart failure models demonstrating improved ejection fraction, reversed remodeling, and reduced pulmonary congestion without major safety signals �the company is advancing NP-MP1 toward clinical translation, with the ambition to transform treatment for heart failure with reduced ejection fraction (HFrEF).